Comparing Ticagrelor with Low-dose Aspirin to Regular Aspirin for Heart Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the safety and effectiveness of Ticagrelor combined with low-dose Aspirin versus standard dual anti-platelet therapy in patients with acute coronary syndrome (ACS) who are at high risk for ischemic events following percutaneous coronary intervention (PCI). A total of 1220 patients will be enrolled and randomly assigned to receive either Ticagrelor with low-dose Aspirin or Ticagrelor with regular-dose Aspirin for a duration of 12 months. The primary goal is to assess the impact on major adverse cardiac and cerebral events, while secondary objectives include evaluating bleeding events, platelet function inhibition, and medication adherence. This research seeks to provide new insights into anti-platelet protocols for high-risk ACS patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ACS patients at high risk for ischemic events after successful PCI with implantation of at least one drug eluting stent
* Able and willing to provide informed consent and participate in 12 months follow-up period
* Able to receive DAPT treatment
* Enrollment into the study will require meeting at least one angiographic or clinical inclusion and none of the exclusion criteria.

Clinical inclusion criteria:

1. Family history of premature coronary heart disease (Coronary heart disease in first-degree male relative \<55 years old or in first-degree female relative \<65 years old)
2. Repeated myocardial infarction
3. Positive serum cardiac troponin I/T
4. Combined with at least one organ/system with atherosclerotic disease (e.g. intracranial or peripheral arteries)
5. Type 2 diabetes mellitus under medication
6. Chronic kidney disease (eGFR\<60 mL/min/1.73 m2 or CrCl\<60ml/min)

Angiographic Inclusion Criteria:

1. LM lesion requiring stents
2. Proximal LAD lesion(s) requiring stents
3. Bypass grafts lesion(s) requiring stents
4. Overall stent length ≥60 mm
5. History of in-stent thrombosis
6. Bifurcation lesions requiring at least 2 stents
7. Over two vessels lesions requiring stents
8. Calcified target lesion(s) requiring atherectomy
9. The intraoperative occurrence of no-reflow or slow-flow
10. Compressed branch vessels with a diameter of at least 2.0 mm failing to reach flow restoration (at least TIMI 3)

Exclusion Criteria:

* Need for chronic oral anticoagulation
* With cardiomyopathy（HCM/DCM/RCM）
* With severe ventricular arrhythmia requiring ICD implantation
* With chronic respiratory disease (COPD, asthma, chronic bronchitis, pulmonary heart disease)
* With severe infectious disease（active hepatitis B, active hepatitis C, AIDS）
* With hematological disorders（thrombocytopenia, severe anemia, leukaemia）
* With severe liver disease or kidney failure
* With malignant tumor
* With cognitive impairment
* Unable or unwilling to provide informed consent or undergo follow-up

Where it's running

• Fuwai Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Haiyan Qian, MD, PhD — Fuwai Hospital, Beijing, China
• Study coordinator: Haiyan Qian, MD, PhD
• Email: ahqhy712@163.com
• Phone: +8613811386143

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Common femoral vein-to-artery diameter ratio to detect elevated LVEDP

  Researchers test whether the ratio of the common femoral vein to artery diameters, measured by ultrasound, can flag elevated LV end-diastolic pressure in patients having coronary angiography.

  Recruiting Burapha University · Chon Buri · NCT07866859

• Intrahospital flu vaccine for adults with high cardiovascular risk when admitted for ACS or heart failure

  This study tests whether offering a flu vaccine at the bedside during a hospital stay, along with counseling, increases vaccination rates for adults with acute coronary syndrome or heart failure who are at high cardiovascular risk.

  Recruiting at 2 sites University Hospital of Cologne · Cologne and 1 other locations · NCT07721649

• Digital lifestyle platform after rehabilitation to support self-management

  A digital, patient-facing platform is being tested to see if people who recently finished inpatient rehabilitation will use it and benefit from personalized lifestyle guidance at home.

  Recruiting at 2 sites Insel Gruppe AG, University Hospital Bern · Bern, Canton of Bern and 1 other locations · NCT07597031

• AI-driven Medipixel fractional flow reserve to guide PCI

  This test checks whether an AI-based, angiography-derived Medipixel FFR method can guide PCI as safely and effectively as standard invasive pressure-wire FFR in adults with coronary artery disease.

  Recruiting at 23 sites Samsung Medical Center · Seoul, Select State and 22 other locations · NCT07329699

• Supira System in high-risk PCI: a pivotal comparison to Impella

  This study tests whether the Supira System can safely and effectively support the heart during high-risk PCI, compared with the currently available Impella device.

  Recruiting at 26 sites Supira Medical · Loma Linda, California and 25 other locations · NCT07296744

• Freesolve resorbable magnesium scaffold vs. Xience stent for up to two new heart artery lesions

  This trial tests whether the Freesolve resorbable magnesium scaffold works as well as the Xience drug-eluting stent for treating up to two new coronary artery lesions in adults.

  Recruiting at 3 sites Teleflex · Washington D.C., District of Columbia and 2 other locations · NCT07258290

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.